I think VK5211 has to potential to become a blockbuster drug someday (300,000 hip fracture cases annually in the U.S. alone). Pro-athletes and bodybuilders already using SARMs off label with success. Looking forward to phase 2 data this quarter. VKTX is up 200% in the last two months but is still way below it's IPO price of $10.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.